LAB - Standard BioTools Inc.
NEXT EARNINGS:
May 4, 2026
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$3.25
DETAILS
HIGH:
$3.25
LOW:
$3.25
MEDIAN:
$3.25
CONSENSUS:
$3.25
UPSIDE:
182.61%
Market Cap:
442.25M
Volume:
1,237,297
Avg Volume:
1,654,103
52 Week Range:
0.92-1.72
Sector:
Healthcare
Industry:
Medical - Devices
Beta:
1.33
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
814
IPO Date:
2011-02-10
EPS (TTM):
-0.52
P/E Ratio:
-6.52
Revenue (TTM):
174.43M
Total Assets:
612.34M
Total Debt:
33.00M
Cash & Equiv:
166.73M
Rev Growth (5Y):
8.3%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-24.7%
Debt/Equity:
0.07
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-24 | $-0.15 | $-0.03 | -401.8% | $3.2M | $18.5M | -82.6% |
| 2025-11-04 | $-0.04 | $-0.03 | -60.0% | $19.6M | $18.5M | +5.7% |
| 2025-08-11 | $-0.04 | $-0.04 | 0.0% | $21.8M | $40.9M | -46.7% |
| 2025-05-06 | $-0.04 | $-0.04 | 0.0% | $40.8M | $39.2M | +4.0% |
| 2025-02-26 | $-0.05 | $-0.07 | +28.6% | $46.7M | $43.0M | +8.6% |
| 2024-10-30 | $-0.05 | $-0.08 | +37.5% | $45.0M | $43.0M | +4.5% |
| 2024-07-31 | $-0.08 | $-0.06 | -33.3% | $37.2M | $41.3M | -9.9% |
| 2024-05-08 | $-0.23 | $-0.09 | -155.6% | $45.5M | $46.0M | -1.0% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 174.43M | 106.34M | 97.95M | 130.58M | 138.14M | 117.24M | 112.96M | 101.94M | 104.45M | 114.71M | 116.46M | 71.18M |
| Net Income | (138.88M) | (74.66M) | (190.10M) | (59.24M) | (53.02M) | (64.79M) | (59.01M) | (60.53M) | (75.98M) | (53.31M) | (52.83M) | (15.82M) |
| EPS | -0.52 | -0.94 | -2.43 | -0.78 | -0.74 | -0.97 | -1.49 | -1.84 | -2.62 | -1.86 | -1.90 | -0.62 |
| Total Assets | 612.34M | 323.07M | 390.31M | 275.21M | 324.76M | 264.81M | 303.65M | 287.35M | 306.39M | 371.06M | 407.56M | 116.92M |
| Total Debt | 33.00M | 98.21M | 102.66M | 111.65M | 95.38M | 59.98M | 172.06M | 195.24M | 194.95M | 195.68M | 195.46M | 0 |
| Cash & Equivalents | 166.73M | 51.70M | 81.31M | 28.45M | 68.52M | 21.66M | 95.40M | 58.06M | 35.05M | 29.12M | 33.71M | 35.26M |
| Operating Cash Flow | (143.45M) | (43.29M) | (89.37M) | (44.06M) | (15.42M) | (35.21M) | (25.20M) | (24.10M) | (39.10M) | (34.70M) | (22.62M) | (1.59M) |
| Free Cash Flow | (151.81M) | (46.12M) | (93.19M) | (57.33M) | (28.13M) | (37.74M) | (25.57M) | (25.71M) | (44.16M) | (45.35M) | (30.03M) | (6.28M) |
| FCF per Share | -0.43 | -0.58 | -1.19 | -0.76 | -0.39 | -0.57 | -0.64 | -0.78 | -1.52 | -1.58 | -1.08 | -0.25 |
| Book Value | 471.72M | (148.05M) | (81.47M) | 94.60M | 139.05M | 153.61M | 72.12M | 30.93M | 53.23M | 114.90M | 150.42M | 97.12M |
| Cash & ST Investments | 292.87M | 114.89M | 165.78M | 28.45M | 68.52M | 58.64M | 95.40M | 63.14M | 59.43M | 94.97M | 115.30M | 84.34M |
| ROC Equity | -0.29 | N/A | N/A | -0.63 | -0.38 | -0.42 | -0.82 | -1.96 | -1.43 | -0.46 | -0.35 | -0.16 |